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A Word of Caution
The study by De Luca et al. (1) elegantly demonstrates that
increasing doses of intracoronary adenosine are associated with
incremental reductions in fractional flow reserve. We would like
to caution, however, against high-dose intracoronary adenosine
administration in the right coronary artery. Although none of
the 12 patients who underwent right coronary artery evaluation
in the present study had a clinical event, 3 of them developed
complete atrioventricular block lasting 4 s. Prolonged complete
atrioventricular block can lead to ventricular fibrillation or atrial
fibrillation (2), both important complications that may require emer-
gent defibrillation. Hence, intravenous administration may be the
preferred route for vasodilator administration for fractional flow
reserve measurement in the right coronary artery.
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Reply
We would like to thank Drs. Brilakis and Banerjee for their
interest in our study (1). In our extensive experience (1,2), we have
never had any relevant complications, especially atrial or ventricular
fibrillation, with adenosine administration in the right coronary artery.
This is consistent with data shown by other authors (3).
As stated in our paper (1), we had to stop the protocol in 4
atients due to atrioventricular block that technically hampered the
valuation of fractional flow reserve. Therefore, we believe that it
s not worthwhile to increase the dose of adenosine in the
valuation of fractional flow reserve when there is already a relevant
trioventricular block with a low dose.
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